Vol. 25/No. 13

home / publications / oncology-live / vol-25-no-13

John Strickler, MD, of Duke Cancer Institute

Effectively Targeting c-Met in Colorectal Cancer Is Becoming a Reality With Novel Approaches

Megan Hollasch
October 31st 2024
ArticlePathways

John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.

John L. Marshall, MD, of Georgetown Lombardi Comprehensive Cancer Center

ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting

Megan Hollasch
October 28th 2024
ArticleCover Story

John L. Marshall, MD, details updates with ctDNA in colorectal cancer, and how precision medicine with ctDNA could change the way patients are treated.

Ramya Thota, MD, of Intermountain Health

A Multipronged Approach Can Address Disparities in Cancer Care for Patients in Rural Communities

Kyle Doherty
October 27th 2024
ArticleOncology Business Management

Investigators are examining and implementing several innovations that they hope will combat the persistent issue of limited access to cancer care for patients living in rural areas.

Wenxin “Vincent” Xu, MD

Immunotherapy Combinations Dominate Frontline Discussions in Advanced RCC

Kyle Doherty
October 25th 2024
ArticlePeer Exchange

A panel of experts detail updated data and developments in the advanced renal cell carcinoma space with immunotherapy-based combination regimens.

Maurie Markman, MD

The Escalating Need for Robust Decision Support in Oncology: Ovarian Cancer as an Example

Maurie Markman, MD
October 24th 2024
ArticleFrom the Editor

The speed at which new drugs, combinations, and novel approaches are being introduced into routine practice presents a challenge for treating oncologists